

ASX Announcement

17 September 2015

Appendix 3B - Issue of new Performance Rights & Retention Rights

Please find attached an Appendix 3B giving details of the issue of 276,261 new Performance Rights and 210,916 new Retention Rights.

For more information, please contact:

David Griffith, Managing Director Malcolm Mitchell, Group Chief Financial Officer Ph: +61 2 9393 0301

About IPH Limited

IPH Limited ("IPH", ASX:IPH) is the holding company of Spruson & Ferguson and Fisher Adams Kelly, which comprise the leading intellectual property ("IP") services group in the Asia-Pacific region, offering a wide range of services for the protection, commercialisation, enforcement and management of IP. These services are provided across Australia, New Zealand, Papua New Guinea, the Pacific Islands and Asia from offices in Sydney, Singapore, Kuala Lumpur and supported by a representative office in Shanghai. The firm comprises a multidisciplinary team of approximately 300 people, including some of the most highly regarded IP professionals in the Asia-Pacific region. The team services a diverse client base of Fortune Global 500 companies and other multinationals, public sector research organisations, foreign associates and local clients. IPH is the first IP services firm to list on the Australian Stock Exchange.

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity	
IPH Limited	
ABN	
49 169 015 838	

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- +Class of +securities issued or to be issued
- i. Performance Rights
- 2. Retention Rights
- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- 1. 276,261 Performance Rights
- 2. 210,916 Retention Rights

- **Principal** of the terms 3 +securities (e.g. if options, exercise price and expiry date; if paid +securities. amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)
- Vesting of Performance Rights occurs on 8 September 2018.

The number of Performance Rights on two which vest will depend performance conditions, 50% of the Performance Rights are subject to the performance condition of Shareholder Return (TSR) and the remaining 50% of the Performance Rights are subject to the performance condition of Earnings Per Share (EPS), these performance each of conditions being tested at the end of the measurement period of 3 years.

Any Performance Rights which do not vest on 8 September 2018, will lapse.

All Performance Rights have a nil exercise price.

Vested Performance Rights can be converted into Fully Paid Ordinary Shares in the capital of IPH Limited, in accordance with the terms of grant.

2. Vesting of Retention Rights occurs in three tranches. The first tranche will vest on 1 July 2016, the second tranche will vest on 1 July 2017 and the third tranche will vest on 1 July 2018.

The Retention Rights are subject to a service condition and will vest if the participant continues to be employed by a member of the IPH group on the relevant vesting date.

Any Retention Rights which do not vest on their relevant vesting date, will lapse.

All Retention Rights have a nil exercise price.

Vested Retention Rights can be converted into Fully Paid Ordinary Shares in the capital of IPH Limited, in accordance with the terms of grant.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 1. After 8 September 2018, vested Performance Rights can be converted into Fully Paid Ordinary Shares in the capital of IPH Limited in accordance with the terms of grant. Fully Paid Ordinary Shares resulting from that conversion will rank equally with other Fully Paid Ordinary Shares then on issue.
- 2. After each vesting date (1 July 2016, 1 July 2017 and 1 July 2018), vested Retention Rights can be converted into Fully Paid Ordinary Shares in the capital of IPH Limited in accordance with the terms of grant. Fully Paid Ordinary Shares resulting from that conversion will rank equally with other Fully Paid Ordinary Shares then on issue.
- 5 Issue price or consideration
- ı. Nil
- 2. Nil
- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)
- Grant of Performance Rights
- 2. Grant of Retention Rights

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

No

6b The date the security holder resolution under rule 7.1A was passed

N/A

6c Number of *securities issued without security holder approval under rule 7.1

N/A

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued	N/A	
	under an exception in rule 7.2	,	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer to Annexure 1	
7	⁺ Issue dates	1. 17 September 2015	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	2. 17 September 2015	
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	163,407,275	Ordinary Shares

9 Number and *class of all *securities not quoted on ASX (*including* the *securities in section 2 if applicable)

Number	+Class
551,969	Performance Rights
	issued under the
	Long Term Incentive
	Plan published on
	the ASX on 17
	November 2014
353,773	Retention Rights
	issued under the
	Retention Plan
	published on the
	ASX on 17 November
	2014

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Fully Paid Ordinary Shares resulting from the conversion of Performance Rights and Retention Rights will have the same dividend policy as the Fully Paid Ordinary Shares then on issue, from the date of issue

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A

18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A

30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type (tick o	of ⁺ securities one)
(a)		⁺ Securities described in Part 1
(b)		All other ⁺ securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 100,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	N/A	
39	⁺ Class of ⁺ securities for which quotation is sought	N/A	
		[· ·	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Number N/A	⁺ Class

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

	Millielle		
C: 1			17 September 2015
Sign here:	(D: /G	Date:	
	(Director/ Company secretary)		
	Malcolm Mitchell		
Print name:			

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate "A", the base figures capacity is calculated	ure from which the placement
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	157,559,499
Add the following:	
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an exception in rule 7.2	
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval	
 Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period 	
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	N/A
"A"	157,559,499

Step 2: Calculate 15% of "A"	
"B"	0.15 [Note: this value cannot be changed]
Multiply "A" by 0.15	23,633,925
Step 3: Calculate "C", the amount that has already been used	of placement capacity under rule 7.1
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	5,847,776
 Under an exception in rule 7.2 	
Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	5,847,776
Step 4: Subtract "C" from ["A" x "l placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	23,633,925
Note: number must be same as shown in Step 2	
Subtract "C"	5,847,776
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	17,786,149
	[Note: this is the remaining placement capacity under rule 7.1]

Part 2

Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
"A" Note: number must be same as shown in Step 1 of Part 1	N/A
Step 2: Calculate 10% of "A"	
"D"	0.10 Note: this value cannot be changed
Multiply "A" by 0.10	N/A
7.1A that has already been used Insert number of *equity securities issued	of placement capacity under rule
or agreed to be issued in that 12 month period under rule 7.1A	N/A
or agreed to be issued in that 12 month	N/A

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	N/A
Note: number must be same as shown in Step 2	
Subtract "E"	N/A
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	N/A
	Note: this is the remaining placement capacity under rule 7.1A